Recurrent Pregnancy Loss Clinical Trial
Official title:
Maternal and Newborn Safety Profile of Progestogens in EARLY Pregnancy
This multinational, prospective, active surveillance, registry study following two cohorts will include study participants who are pregnant and seeking any type of medical treatment, including dydrogesterone and other progestogens, for either (A) recurrent pregnancy loss and/or bleeding in early pregnancy or (B) as In-Vitro Fertilization (IVF)/Assissted Reproductive Technology (ART) support. Pregnant women not taking progestogen and are advised an alternative non-medical treatment, in the context of bleeding in early pregnancy, recurrent pregnancy loss, or undergoing natural cycle frozen embryo transfer (NC-FET) can also be included in this study. Eligible study participants will be recruited via an international network of prescribing Health Care Practitioners (HCPs) in China, Turkey, and Russia with the aim to collect data related to maternal safety and newborn safety in women prescribed progestogens during early pregnancy. Study participants will be followed from early pregnancy until 6 - 12 weeks after giving birth. All malformations will be captured via direct contacts with the study participants. Study participants will be sent online questionnaires via the electronic Patient Reported Outcomes (ePRO) solution provided by MediData. Major malformations reported by the study participants will be validated by ZEG Berlin via relevant source documents and if necessary, via contacting the treating HCPs. The total study duration is planned for approximately 4 years including recruitment and follow-up.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04718233 -
Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss
|
Phase 2 | |
Recruiting |
NCT01946945 -
Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis
|
Phase 2 | |
Completed |
NCT02572154 -
Sperm DNA Fragmentation in Recurrent Pregnancy Loss
|
N/A | |
Completed |
NCT03174951 -
Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss
|
Phase 2 | |
Recruiting |
NCT05444283 -
Genomic Predictors of Recurrent Pregnancy Loss
|
||
Active, not recruiting |
NCT04621773 -
Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
|
||
Recruiting |
NCT02990403 -
The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
|
Phase 4 | |
Recruiting |
NCT02990390 -
The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla
|
N/A | |
Not yet recruiting |
NCT05612620 -
Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss
|
||
Not yet recruiting |
NCT05520112 -
Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells
|
Phase 1/Phase 2 | |
Suspended |
NCT04397042 -
SCUBE-1 and Carotid Intima Media Thickness in Recurrent Pregnancy Loss
|
||
Not yet recruiting |
NCT05341856 -
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL
|
Early Phase 1 | |
Recruiting |
NCT06007560 -
Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss
|
N/A | |
Completed |
NCT02386384 -
TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure
|
N/A | |
Recruiting |
NCT01635426 -
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages
|
Phase 2/Phase 3 | |
Suspended |
NCT01546350 -
Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH
|
Phase 2 | |
Completed |
NCT00721591 -
Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
|
N/A | |
Terminated |
NCT00564174 -
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
|
N/A | |
Completed |
NCT04455256 -
Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss
|
||
Not yet recruiting |
NCT05237843 -
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss
|
Phase 1 |